11 results
424B5
LIXT
Lixte Biotechnology Holdings Inc
14 Apr 22
Prospectus supplement for primary offering
6:15am
at which we can recruit patients to participate in clinical trials of our product candidate, and we may experience delays in our clinical trials if we
424B5
LIXT
Lixte Biotechnology Holdings Inc
1 Mar 21
Prospectus supplement for primary offering
4:21pm
is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical
8-K
EX-10.1
uf6mczm2j5y
22 Jan 21
Entry into a Material Definitive Agreement
2:00pm
424B4
dt7wo1cfem
27 Nov 20
Prospectus supplement with pricing info
5:25pm
S-1/A
azgasgoxb14wb fml
13 Oct 20
IPO registration (amended)
10:00am
S-1
mt4pi2a15
3 Sep 20
IPO registration
5:05pm
- Prev
- 1
- Next